Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt
Executive Summary
Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.
You may also be interested in...
Bausch + Lomb’s First Results Look Familiar
January-March results Bausch + Lomb reported on 8 June were included in Bausch Health’s results published in May on the same day it closed an IPO shares to separate its eye health and vision care business. Guidance it provided, however, was new and a first for Bausch + Lomb.
Independence Arrives For Bausch + Lomb Through IPO Priced Lower Than Forecast
Bausch Health shopped Bausch + Lomb IPO at share price between $21 and $24. In trading of nearly 14.4m shares on New York exchange, Bausch + Lomb’s share price stayed above opening $18.50 and reached $20.07 before closing at $20, up 11.11%.
Preparing For Expansion: Perrigo Sets $500M Private Offering, Bausch + Lomb IPO Details Filed
Perrigo intends to use net proceeds from $500m private offering along with cash on hand and funds from previous credit facilities to finance acquisition of HRA Pharma. Bausch Health reduces debt by $200m as it prepares to target proceeds from planned Bausch + Lomb IPO also to paying down debt.